| 47.7486 -0.011 (-0.02%) | 08-12 13:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 59.68  |
1-year : | 69.71 |
| Resists | First : | 51.09 |
Second : | 59.68 |
| Pivot price | 37.54 |
|||
| Supports | First : | 38.4 |
Second : | 30.54 |
| MAs | MA(5) : | 42.63 |
MA(20) : | 36.41 |
| MA(100) : | 30.29 |
MA(250) : | 25.74 |
|
| MACD | MACD : | 2.7 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 87.6 |
D(3) : | 85.4 |
| RSI | RSI(14): 78.6 |
|||
| 52-week | High : | 51.09 | Low : | 10.73 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SEPN ] has closed above the upper band by 6.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 217.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 48.04 - 48.24 | 48.24 - 48.42 |
| Low: | 38.22 - 38.4 | 38.4 - 38.57 |
| Close: | 47.41 - 47.75 | 47.75 - 48.08 |
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Wed, 12 Aug 2026
Septerna (NASDAQ:SEPN) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
Wed, 12 Aug 2026
A Quick Look at Today's Ratings for Septerna(SEPN.US), With a Forecast Between $49 to $60 - Moomoo
Wed, 12 Aug 2026
Septerna (NASDAQ:SEPN) Price Target Raised to $50.00 at Wells Fargo & Company - MarketBeat
Wed, 12 Aug 2026
H.C. Wainwright raises Septerna stock price target to $60 on SEP-479 progress - Investing.com
Wed, 12 Aug 2026
SEPN Maintained by HC Wainwright & Co. -- Price Target Raised to $60 - GuruFocus
Wed, 12 Aug 2026
Septerna Shares (SEPN) Surge 23% Following Positive SEP-479 Signal, Exceeding Analyst Predictions - TechStock²
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 2.317e+007 (%) |
| Held by Institutions | 3.1 (%) |
| Shares Short | 2,670 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.656e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -49.9 % |
| Operating Margin | -50.2 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 108 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 3.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|